M&As this week: Celgene, Intrexon Corporation

26 January 2017 (Last Updated January 26th, 2017 18:30)

US-based pharmaceutical company Celgene Corporation has reached an agreement to acquire Delinia for a consideration of $775m, which includes an initial payment of $300m and continent payments up to $475m upon achievement of certain development, regulatory and commercial milestones.

US-based pharmaceutical company Celgene Corporation has reached an agreement to acquire Delinia for a consideration of $775m, which includes an initial payment of $300m and continent payments up to $475m upon achievement of certain development, regulatory and commercial milestones.

Both companies involved in the transaction are based in the US.

"US-based synthetic biology company Intrexon Corporation has signed a definitive agreement to acquire GenVec."

Celgene aims to expand its inflammation and immunology pipeline for the treatment of autoimmune disorders through the acquisition.

US-based synthetic biology company Intrexon Corporation has signed a definitive agreement to acquire GenVec.

Also based in the US, the target company is a developer of gene delivery technology.

Intexron expects the acquisition will help expand its gene delivery platform to target complex multi-gene disorders.